Quick Read Sellas Life Sciences (SLS) has surged 346% over the past year to $5.04 as its Phase 3 REGAL trial for GPS, a WT1-targeting cancer vaccine in AML patients, approaches completion with 72 of ...

Add Yahoo as a preferred source to see more of our stories on Google. Tatiana Schlossberg's surprising revelation that she is battling terminal cancer has put a spotlight on the type of cancer with ...

Net loss in FY25 narrowed to $26.9 million from $30.9 million a year ago, with R&D costs falling to $16 million. ・Phase 3 Regal AML trial nears final analysis, with 72 of 80 required survival events ...

Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, and Blood Cancer United® (formerly The Leukemia & Lymphoma Society), the largest global ...

Preclinical data show that SLS009 lowers the apoptotic threshold in AML cells by suppressing critical survival pathways -NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc.

WASHINGTON, Jan. 14, 2026 /PRNewswire/ -- Blood Cancer United®, formerly The Leukemia & Lymphoma Society, announced today that the first patient has received treatment in a new sub-study of its Beat ...

New trial data suggest azacitidine-venetoclax may rival 7+3 in AML, shifting induction toward targeted, less toxic combinations.

Several patients with acute myeloid leukemia (AML) who were treated with SENTI-202, a chimeric antigen receptor natural killer (CAR-NK) therapy, experienced complete remission after not responding to ...

Ateganosine combined with Libtayo shows improved progression-free survival in advanced non-small cell lung cancer, suggesting potential long-term use. Spevatamig, a bispecific antibody, is being ...

Tatiana Schlossberg's surprising revelation that she is battling terminal cancer has put a spotlight on the type of cancer with which she was diagnosed, acute myeloid leukemia. Schlossberg, the ...